FCRL4: A Potential Drug Target and Biomarker (G83417)

Target Name: FCRL4

NCBI ID: G83417

FCRL4

FCRL4: A Potential Drug Target and Biomarker

FCRL4, also known as Immune receptor translocation-associated protein 1, is a protein that is expressed in various tissues and cells throughout the body. It is a member of the immunoglobulin superfamily and is involved in the regulation of immune responses. FCRL4 has been identified as a potential drug target and biomarker for various diseases, including cancer, autoimmune disorders, and neurodegenerative diseases.

FCRL4 functions as a negative regulator of the NF-kappa-B signaling pathway, which is a critical pathway involved in the regulation of immune and inflammatory responses. The NF-kappa-B signaling pathway is a complex network of proteins that mediate the signaling of various cellular processes, including cell growth, differentiation, inflammation, and stress responses. FCRL4 plays a crucial role in the regulation of NF-kappa-B signaling by inhibiting the activity of the nuclear factor kappa B (NFKB), which is a transcription factor that plays a central role in the NF-kappa-B signaling pathway.

FCRL4 is expressed in various tissues and cells, including the brain, spleen, heart, liver, and lymphoid organs. It is also expressed in various cell types, including immune cells, neural cells, and epithelial cells. FCRL4 has been shown to be involved in the regulation of immune responses, including the regulation of T cell development and function, the regulation of B cell proliferation and differentiation, and the regulation of inflammation.

FCRL4 has also been shown to be involved in the regulation of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. These diseases are characterized by the progressive loss of brain cells and the development of progressive neurological symptoms. FCRL4 has been shown to play a role in the regulation of neurodegenerative disease by interacting with the neurotransmitter dopamine, which is involved in the regulation of mood, appetite, and movement.

FCRL4 has also been shown to be involved in the regulation of cancer, including the regulation of cell proliferation and the development of cancer cells. Cancer is a disease characterized by the rapid and uncontrolled growth of cells, which can lead to the development of a variety of diseases, including breast cancer, lung cancer, and colorectal cancer. FCRL4 has been shown to play a role in the regulation of cancer cell proliferation by inhibiting the activity of the oncogene transforming growth factor (TGF-1), which is involved in the regulation of cell growth and differentiation.

FCRL4 has also been shown to be involved in the regulation of autoimmune disorders, including rheumatoid arthritis, lupus, and multiple sclerosis. These disorders are characterized by the development of autoimmune responses that lead to inflammation and damage to body tissues. FCRL4 has been shown to play a role in the regulation of autoimmune disorders by interacting with the autoantibody rheumatoid factor (RF), which is involved in the regulation of autoimmune responses.

In conclusion, FCRL4 is a protein that is involved in the regulation of various physiological processes in the body. It has been identified as a potential drug target and biomarker for a variety of diseases, including cancer, autoimmune disorders, and neurodegenerative diseases. Further research is needed to fully understand the role of FCRL4 in these diseases and to develop effective treatments.

Protein Name: Fc Receptor Like 4

Functions: May function as an inhibitor of the B-cell receptor signaling. May function in the B-cell-mediated immune response

The "FCRL4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FCRL4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets